The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Targeted Drugs for NSCLC Market Research Report 2025
Synopsis
The global Targeted Drugs for NSCLC market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Targeted Drugs for NSCLC, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Targeted Drugs for NSCLC.
Report Scope
The Targeted Drugs for NSCLC market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Targeted Drugs for NSCLC market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Targeted Drugs for NSCLC companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Allergan
Amgen
ARIAD Pharmaceuticals (Takeda)
Beacon Pharma Limited
BeiGene
Biocon
Boehringer-Ingelheim
Celgene Corporation
Drug International Limted
Fujifilm Kyowa Kirin Biologics
Genvio Pharma Limited
Hetero Drugs
ImClone Systems (Eli Lilly)
Incepta Pharmaceuticals
Mylan
Novartis
Pfizer
Reliance Lifesciences
Roche
AstraZeneca
Cipla
Teva
OSI Pharmaceuticals
Glenmark Pharmaceuticals
Natco Pharma
Segment by Type
Target EGFR
Target ALK
Target HER2
Target ROS1
Target BRAF
Target MEK
Target VEGFR2
Target VEGF
Target MET
Segment by Application
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Targeted Drugs for NSCLC companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Targeted Drugs for NSCLC market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Targeted Drugs for NSCLC, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Targeted Drugs for NSCLC.
Report Scope
The Targeted Drugs for NSCLC market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Targeted Drugs for NSCLC market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Targeted Drugs for NSCLC companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Allergan
Amgen
ARIAD Pharmaceuticals (Takeda)
Beacon Pharma Limited
BeiGene
Biocon
Boehringer-Ingelheim
Celgene Corporation
Drug International Limted
Fujifilm Kyowa Kirin Biologics
Genvio Pharma Limited
Hetero Drugs
ImClone Systems (Eli Lilly)
Incepta Pharmaceuticals
Mylan
Novartis
Pfizer
Reliance Lifesciences
Roche
AstraZeneca
Cipla
Teva
OSI Pharmaceuticals
Glenmark Pharmaceuticals
Natco Pharma
Segment by Type
Target EGFR
Target ALK
Target HER2
Target ROS1
Target BRAF
Target MEK
Target VEGFR2
Target VEGF
Target MET
Segment by Application
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Targeted Drugs for NSCLC companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Targeted Drugs for NSCLC Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Target EGFR
1.2.3 Target ALK
1.2.4 Target HER2
1.2.5 Target ROS1
1.2.6 Target BRAF
1.2.7 Target MEK
1.2.8 Target VEGFR2
1.2.9 Target VEGF
1.2.10 Target MET
1.3 Market by Application
1.3.1 Global Targeted Drugs for NSCLC Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Squamous Cell Carcinoma of NSCLC
1.3.3 Adenocarcinoma of NSCLC
1.3.4 Large Cell Carcinoma of NSCLC
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Targeted Drugs for NSCLC Market Perspective (2019-2030)
2.2 Targeted Drugs for NSCLC Growth Trends by Region
2.2.1 Global Targeted Drugs for NSCLC Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Targeted Drugs for NSCLC Historic Market Size by Region (2019-2024)
2.2.3 Targeted Drugs for NSCLC Forecasted Market Size by Region (2025-2030)
2.3 Targeted Drugs for NSCLC Market Dynamics
2.3.1 Targeted Drugs for NSCLC Industry Trends
2.3.2 Targeted Drugs for NSCLC Market Drivers
2.3.3 Targeted Drugs for NSCLC Market Challenges
2.3.4 Targeted Drugs for NSCLC Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Targeted Drugs for NSCLC Players by Revenue
3.1.1 Global Top Targeted Drugs for NSCLC Players by Revenue (2019-2024)
3.1.2 Global Targeted Drugs for NSCLC Revenue Market Share by Players (2019-2024)
3.2 Global Targeted Drugs for NSCLC Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Targeted Drugs for NSCLC Revenue
3.4 Global Targeted Drugs for NSCLC Market Concentration Ratio
3.4.1 Global Targeted Drugs for NSCLC Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Targeted Drugs for NSCLC Revenue in 2023
3.5 Targeted Drugs for NSCLC Key Players Head office and Area Served
3.6 Key Players Targeted Drugs for NSCLC Product Solution and Service
3.7 Date of Enter into Targeted Drugs for NSCLC Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Targeted Drugs for NSCLC Breakdown Data by Type
4.1 Global Targeted Drugs for NSCLC Historic Market Size by Type (2019-2024)
4.2 Global Targeted Drugs for NSCLC Forecasted Market Size by Type (2025-2030)
5 Targeted Drugs for NSCLC Breakdown Data by Application
5.1 Global Targeted Drugs for NSCLC Historic Market Size by Application (2019-2024)
5.2 Global Targeted Drugs for NSCLC Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Targeted Drugs for NSCLC Market Size (2019-2030)
6.2 North America Targeted Drugs for NSCLC Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Targeted Drugs for NSCLC Market Size by Country (2019-2024)
6.4 North America Targeted Drugs for NSCLC Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Targeted Drugs for NSCLC Market Size (2019-2030)
7.2 Europe Targeted Drugs for NSCLC Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Targeted Drugs for NSCLC Market Size by Country (2019-2024)
7.4 Europe Targeted Drugs for NSCLC Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Targeted Drugs for NSCLC Market Size (2019-2030)
8.2 Asia-Pacific Targeted Drugs for NSCLC Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Targeted Drugs for NSCLC Market Size by Region (2019-2024)
8.4 Asia-Pacific Targeted Drugs for NSCLC Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Targeted Drugs for NSCLC Market Size (2019-2030)
9.2 Latin America Targeted Drugs for NSCLC Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Targeted Drugs for NSCLC Market Size by Country (2019-2024)
9.4 Latin America Targeted Drugs for NSCLC Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Targeted Drugs for NSCLC Market Size (2019-2030)
10.2 Middle East & Africa Targeted Drugs for NSCLC Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Targeted Drugs for NSCLC Market Size by Country (2019-2024)
10.4 Middle East & Africa Targeted Drugs for NSCLC Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Allergan
11.1.1 Allergan Company Detail
11.1.2 Allergan Business Overview
11.1.3 Allergan Targeted Drugs for NSCLC Introduction
11.1.4 Allergan Revenue in Targeted Drugs for NSCLC Business (2019-2024)
11.1.5 Allergan Recent Development
11.2 Amgen
11.2.1 Amgen Company Detail
11.2.2 Amgen Business Overview
11.2.3 Amgen Targeted Drugs for NSCLC Introduction
11.2.4 Amgen Revenue in Targeted Drugs for NSCLC Business (2019-2024)
11.2.5 Amgen Recent Development
11.3 ARIAD Pharmaceuticals (Takeda)
11.3.1 ARIAD Pharmaceuticals (Takeda) Company Detail
11.3.2 ARIAD Pharmaceuticals (Takeda) Business Overview
11.3.3 ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Introduction
11.3.4 ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drugs for NSCLC Business (2019-2024)
11.3.5 ARIAD Pharmaceuticals (Takeda) Recent Development
11.4 Beacon Pharma Limited
11.4.1 Beacon Pharma Limited Company Detail
11.4.2 Beacon Pharma Limited Business Overview
11.4.3 Beacon Pharma Limited Targeted Drugs for NSCLC Introduction
11.4.4 Beacon Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2019-2024)
11.4.5 Beacon Pharma Limited Recent Development
11.5 BeiGene
11.5.1 BeiGene Company Detail
11.5.2 BeiGene Business Overview
11.5.3 BeiGene Targeted Drugs for NSCLC Introduction
11.5.4 BeiGene Revenue in Targeted Drugs for NSCLC Business (2019-2024)
11.5.5 BeiGene Recent Development
11.6 Biocon
11.6.1 Biocon Company Detail
11.6.2 Biocon Business Overview
11.6.3 Biocon Targeted Drugs for NSCLC Introduction
11.6.4 Biocon Revenue in Targeted Drugs for NSCLC Business (2019-2024)
11.6.5 Biocon Recent Development
11.7 Boehringer-Ingelheim
11.7.1 Boehringer-Ingelheim Company Detail
11.7.2 Boehringer-Ingelheim Business Overview
11.7.3 Boehringer-Ingelheim Targeted Drugs for NSCLC Introduction
11.7.4 Boehringer-Ingelheim Revenue in Targeted Drugs for NSCLC Business (2019-2024)
11.7.5 Boehringer-Ingelheim Recent Development
11.8 Celgene Corporation
11.8.1 Celgene Corporation Company Detail
11.8.2 Celgene Corporation Business Overview
11.8.3 Celgene Corporation Targeted Drugs for NSCLC Introduction
11.8.4 Celgene Corporation Revenue in Targeted Drugs for NSCLC Business (2019-2024)
11.8.5 Celgene Corporation Recent Development
11.9 Drug International Limted
11.9.1 Drug International Limted Company Detail
11.9.2 Drug International Limted Business Overview
11.9.3 Drug International Limted Targeted Drugs for NSCLC Introduction
11.9.4 Drug International Limted Revenue in Targeted Drugs for NSCLC Business (2019-2024)
11.9.5 Drug International Limted Recent Development
11.10 Fujifilm Kyowa Kirin Biologics
11.10.1 Fujifilm Kyowa Kirin Biologics Company Detail
11.10.2 Fujifilm Kyowa Kirin Biologics Business Overview
11.10.3 Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Introduction
11.10.4 Fujifilm Kyowa Kirin Biologics Revenue in Targeted Drugs for NSCLC Business (2019-2024)
11.10.5 Fujifilm Kyowa Kirin Biologics Recent Development
11.11 Genvio Pharma Limited
11.11.1 Genvio Pharma Limited Company Detail
11.11.2 Genvio Pharma Limited Business Overview
11.11.3 Genvio Pharma Limited Targeted Drugs for NSCLC Introduction
11.11.4 Genvio Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2019-2024)
11.11.5 Genvio Pharma Limited Recent Development
11.12 Hetero Drugs
11.12.1 Hetero Drugs Company Detail
11.12.2 Hetero Drugs Business Overview
11.12.3 Hetero Drugs Targeted Drugs for NSCLC Introduction
11.12.4 Hetero Drugs Revenue in Targeted Drugs for NSCLC Business (2019-2024)
11.12.5 Hetero Drugs Recent Development
11.13 ImClone Systems (Eli Lilly)
11.13.1 ImClone Systems (Eli Lilly) Company Detail
11.13.2 ImClone Systems (Eli Lilly) Business Overview
11.13.3 ImClone Systems (Eli Lilly) Targeted Drugs for NSCLC Introduction
11.13.4 ImClone Systems (Eli Lilly) Revenue in Targeted Drugs for NSCLC Business (2019-2024)
11.13.5 ImClone Systems (Eli Lilly) Recent Development
11.14 Incepta Pharmaceuticals
11.14.1 Incepta Pharmaceuticals Company Detail
11.14.2 Incepta Pharmaceuticals Business Overview
11.14.3 Incepta Pharmaceuticals Targeted Drugs for NSCLC Introduction
11.14.4 Incepta Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2019-2024)
11.14.5 Incepta Pharmaceuticals Recent Development
11.15 Mylan
11.15.1 Mylan Company Detail
11.15.2 Mylan Business Overview
11.15.3 Mylan Targeted Drugs for NSCLC Introduction
11.15.4 Mylan Revenue in Targeted Drugs for NSCLC Business (2019-2024)
11.15.5 Mylan Recent Development
11.16 Novartis
11.16.1 Novartis Company Detail
11.16.2 Novartis Business Overview
11.16.3 Novartis Targeted Drugs for NSCLC Introduction
11.16.4 Novartis Revenue in Targeted Drugs for NSCLC Business (2019-2024)
11.16.5 Novartis Recent Development
11.17 Pfizer
11.17.1 Pfizer Company Detail
11.17.2 Pfizer Business Overview
11.17.3 Pfizer Targeted Drugs for NSCLC Introduction
11.17.4 Pfizer Revenue in Targeted Drugs for NSCLC Business (2019-2024)
11.17.5 Pfizer Recent Development
11.18 Reliance Lifesciences
11.18.1 Reliance Lifesciences Company Detail
11.18.2 Reliance Lifesciences Business Overview
11.18.3 Reliance Lifesciences Targeted Drugs for NSCLC Introduction
11.18.4 Reliance Lifesciences Revenue in Targeted Drugs for NSCLC Business (2019-2024)
11.18.5 Reliance Lifesciences Recent Development
11.19 Roche
11.19.1 Roche Company Detail
11.19.2 Roche Business Overview
11.19.3 Roche Targeted Drugs for NSCLC Introduction
11.19.4 Roche Revenue in Targeted Drugs for NSCLC Business (2019-2024)
11.19.5 Roche Recent Development
11.20 AstraZeneca
11.20.1 AstraZeneca Company Detail
11.20.2 AstraZeneca Business Overview
11.20.3 AstraZeneca Targeted Drugs for NSCLC Introduction
11.20.4 AstraZeneca Revenue in Targeted Drugs for NSCLC Business (2019-2024)
11.20.5 AstraZeneca Recent Development
11.21 Cipla
11.21.1 Cipla Company Detail
11.21.2 Cipla Business Overview
11.21.3 Cipla Targeted Drugs for NSCLC Introduction
11.21.4 Cipla Revenue in Targeted Drugs for NSCLC Business (2019-2024)
11.21.5 Cipla Recent Development
11.22 Teva
11.22.1 Teva Company Detail
11.22.2 Teva Business Overview
11.22.3 Teva Targeted Drugs for NSCLC Introduction
11.22.4 Teva Revenue in Targeted Drugs for NSCLC Business (2019-2024)
11.22.5 Teva Recent Development
11.23 OSI Pharmaceuticals
11.23.1 OSI Pharmaceuticals Company Detail
11.23.2 OSI Pharmaceuticals Business Overview
11.23.3 OSI Pharmaceuticals Targeted Drugs for NSCLC Introduction
11.23.4 OSI Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2019-2024)
11.23.5 OSI Pharmaceuticals Recent Development
11.24 Glenmark Pharmaceuticals
11.24.1 Glenmark Pharmaceuticals Company Detail
11.24.2 Glenmark Pharmaceuticals Business Overview
11.24.3 Glenmark Pharmaceuticals Targeted Drugs for NSCLC Introduction
11.24.4 Glenmark Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2019-2024)
11.24.5 Glenmark Pharmaceuticals Recent Development
11.25 Natco Pharma
11.25.1 Natco Pharma Company Detail
11.25.2 Natco Pharma Business Overview
11.25.3 Natco Pharma Targeted Drugs for NSCLC Introduction
11.25.4 Natco Pharma Revenue in Targeted Drugs for NSCLC Business (2019-2024)
11.25.5 Natco Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Targeted Drugs for NSCLC Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Target EGFR
Table 3. Key Players of Target ALK
Table 4. Key Players of Target HER2
Table 5. Key Players of Target ROS1
Table 6. Key Players of Target BRAF
Table 7. Key Players of Target MEK
Table 8. Key Players of Target VEGFR2
Table 9. Key Players of Target VEGF
Table 10. Key Players of Target MET
Table 11. Global Targeted Drugs for NSCLC Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 12. Global Targeted Drugs for NSCLC Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 13. Global Targeted Drugs for NSCLC Market Size by Region (2019-2024) & (US$ Million)
Table 14. Global Targeted Drugs for NSCLC Market Share by Region (2019-2024)
Table 15. Global Targeted Drugs for NSCLC Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 16. Global Targeted Drugs for NSCLC Market Share by Region (2025-2030)
Table 17. Targeted Drugs for NSCLC Market Trends
Table 18. Targeted Drugs for NSCLC Market Drivers
Table 19. Targeted Drugs for NSCLC Market Challenges
Table 20. Targeted Drugs for NSCLC Market Restraints
Table 21. Global Targeted Drugs for NSCLC Revenue by Players (2019-2024) & (US$ Million)
Table 22. Global Targeted Drugs for NSCLC Market Share by Players (2019-2024)
Table 23. Global Top Targeted Drugs for NSCLC Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for NSCLC as of 2023)
Table 24. Ranking of Global Top Targeted Drugs for NSCLC Companies by Revenue (US$ Million) in 2023
Table 25. Global 5 Largest Players Market Share by Targeted Drugs for NSCLC Revenue (CR5 and HHI) & (2019-2024)
Table 26. Key Players Headquarters and Area Served
Table 27. Key Players Targeted Drugs for NSCLC Product Solution and Service
Table 28. Date of Enter into Targeted Drugs for NSCLC Market
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Targeted Drugs for NSCLC Market Size by Type (2019-2024) & (US$ Million)
Table 31. Global Targeted Drugs for NSCLC Revenue Market Share by Type (2019-2024)
Table 32. Global Targeted Drugs for NSCLC Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 33. Global Targeted Drugs for NSCLC Revenue Market Share by Type (2025-2030)
Table 34. Global Targeted Drugs for NSCLC Market Size by Application (2019-2024) & (US$ Million)
Table 35. Global Targeted Drugs for NSCLC Revenue Market Share by Application (2019-2024)
Table 36. Global Targeted Drugs for NSCLC Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 37. Global Targeted Drugs for NSCLC Revenue Market Share by Application (2025-2030)
Table 38. North America Targeted Drugs for NSCLC Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 39. North America Targeted Drugs for NSCLC Market Size by Country (2019-2024) & (US$ Million)
Table 40. North America Targeted Drugs for NSCLC Market Size by Country (2025-2030) & (US$ Million)
Table 41. Europe Targeted Drugs for NSCLC Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Europe Targeted Drugs for NSCLC Market Size by Country (2019-2024) & (US$ Million)
Table 43. Europe Targeted Drugs for NSCLC Market Size by Country (2025-2030) & (US$ Million)
Table 44. Asia-Pacific Targeted Drugs for NSCLC Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 45. Asia-Pacific Targeted Drugs for NSCLC Market Size by Region (2019-2024) & (US$ Million)
Table 46. Asia-Pacific Targeted Drugs for NSCLC Market Size by Region (2025-2030) & (US$ Million)
Table 47. Latin America Targeted Drugs for NSCLC Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 48. Latin America Targeted Drugs for NSCLC Market Size by Country (2019-2024) & (US$ Million)
Table 49. Latin America Targeted Drugs for NSCLC Market Size by Country (2025-2030) & (US$ Million)
Table 50. Middle East & Africa Targeted Drugs for NSCLC Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 51. Middle East & Africa Targeted Drugs for NSCLC Market Size by Country (2019-2024) & (US$ Million)
Table 52. Middle East & Africa Targeted Drugs for NSCLC Market Size by Country (2025-2030) & (US$ Million)
Table 53. Allergan Company Detail
Table 54. Allergan Business Overview
Table 55. Allergan Targeted Drugs for NSCLC Product
Table 56. Allergan Revenue in Targeted Drugs for NSCLC Business (2019-2024) & (US$ Million)
Table 57. Allergan Recent Development
Table 58. Amgen Company Detail
Table 59. Amgen Business Overview
Table 60. Amgen Targeted Drugs for NSCLC Product
Table 61. Amgen Revenue in Targeted Drugs for NSCLC Business (2019-2024) & (US$ Million)
Table 62. Amgen Recent Development
Table 63. ARIAD Pharmaceuticals (Takeda) Company Detail
Table 64. ARIAD Pharmaceuticals (Takeda) Business Overview
Table 65. ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Product
Table 66. ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drugs for NSCLC Business (2019-2024) & (US$ Million)
Table 67. ARIAD Pharmaceuticals (Takeda) Recent Development
Table 68. Beacon Pharma Limited Company Detail
Table 69. Beacon Pharma Limited Business Overview
Table 70. Beacon Pharma Limited Targeted Drugs for NSCLC Product
Table 71. Beacon Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2019-2024) & (US$ Million)
Table 72. Beacon Pharma Limited Recent Development
Table 73. BeiGene Company Detail
Table 74. BeiGene Business Overview
Table 75. BeiGene Targeted Drugs for NSCLC Product
Table 76. BeiGene Revenue in Targeted Drugs for NSCLC Business (2019-2024) & (US$ Million)
Table 77. BeiGene Recent Development
Table 78. Biocon Company Detail
Table 79. Biocon Business Overview
Table 80. Biocon Targeted Drugs for NSCLC Product
Table 81. Biocon Revenue in Targeted Drugs for NSCLC Business (2019-2024) & (US$ Million)
Table 82. Biocon Recent Development
Table 83. Boehringer-Ingelheim Company Detail
Table 84. Boehringer-Ingelheim Business Overview
Table 85. Boehringer-Ingelheim Targeted Drugs for NSCLC Product
Table 86. Boehringer-Ingelheim Revenue in Targeted Drugs for NSCLC Business (2019-2024) & (US$ Million)
Table 87. Boehringer-Ingelheim Recent Development
Table 88. Celgene Corporation Company Detail
Table 89. Celgene Corporation Business Overview
Table 90. Celgene Corporation Targeted Drugs for NSCLC Product
Table 91. Celgene Corporation Revenue in Targeted Drugs for NSCLC Business (2019-2024) & (US$ Million)
Table 92. Celgene Corporation Recent Development
Table 93. Drug International Limted Company Detail
Table 94. Drug International Limted Business Overview
Table 95. Drug International Limted Targeted Drugs for NSCLC Product
Table 96. Drug International Limted Revenue in Targeted Drugs for NSCLC Business (2019-2024) & (US$ Million)
Table 97. Drug International Limted Recent Development
Table 98. Fujifilm Kyowa Kirin Biologics Company Detail
Table 99. Fujifilm Kyowa Kirin Biologics Business Overview
Table 100. Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Product
Table 101. Fujifilm Kyowa Kirin Biologics Revenue in Targeted Drugs for NSCLC Business (2019-2024) & (US$ Million)
Table 102. Fujifilm Kyowa Kirin Biologics Recent Development
Table 103. Genvio Pharma Limited Company Detail
Table 104. Genvio Pharma Limited Business Overview
Table 105. Genvio Pharma Limited Targeted Drugs for NSCLC Product
Table 106. Genvio Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2019-2024) & (US$ Million)
Table 107. Genvio Pharma Limited Recent Development
Table 108. Hetero Drugs Company Detail
Table 109. Hetero Drugs Business Overview
Table 110. Hetero Drugs Targeted Drugs for NSCLC Product
Table 111. Hetero Drugs Revenue in Targeted Drugs for NSCLC Business (2019-2024) & (US$ Million)
Table 112. Hetero Drugs Recent Development
Table 113. ImClone Systems (Eli Lilly) Company Detail
Table 114. ImClone Systems (Eli Lilly) Business Overview
Table 115. ImClone Systems (Eli Lilly) Targeted Drugs for NSCLC Product
Table 116. ImClone Systems (Eli Lilly) Revenue in Targeted Drugs for NSCLC Business (2019-2024) & (US$ Million)
Table 117. ImClone Systems (Eli Lilly) Recent Development
Table 118. Incepta Pharmaceuticals Company Detail
Table 119. Incepta Pharmaceuticals Business Overview
Table 120. Incepta Pharmaceuticals Targeted Drugs for NSCLC Product
Table 121. Incepta Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2019-2024) & (US$ Million)
Table 122. Incepta Pharmaceuticals Recent Development
Table 123. Mylan Company Detail
Table 124. Mylan Business Overview
Table 125. Mylan Targeted Drugs for NSCLC Product
Table 126. Mylan Revenue in Targeted Drugs for NSCLC Business (2019-2024) & (US$ Million)
Table 127. Mylan Recent Development
Table 128. Novartis Company Detail
Table 129. Novartis Business Overview
Table 130. Novartis Targeted Drugs for NSCLC Product
Table 131. Novartis Revenue in Targeted Drugs for NSCLC Business (2019-2024) & (US$ Million)
Table 132. Novartis Recent Development
Table 133. Pfizer Company Detail
Table 134. Pfizer Business Overview
Table 135. Pfizer Targeted Drugs for NSCLC Product
Table 136. Pfizer Revenue in Targeted Drugs for NSCLC Business (2019-2024) & (US$ Million)
Table 137. Pfizer Recent Development
Table 138. Reliance Lifesciences Company Detail
Table 139. Reliance Lifesciences Business Overview
Table 140. Reliance Lifesciences Targeted Drugs for NSCLC Product
Table 141. Reliance Lifesciences Revenue in Targeted Drugs for NSCLC Business (2019-2024) & (US$ Million)
Table 142. Reliance Lifesciences Recent Development
Table 143. Roche Company Detail
Table 144. Roche Business Overview
Table 145. Roche Targeted Drugs for NSCLC Product
Table 146. Roche Revenue in Targeted Drugs for NSCLC Business (2019-2024) & (US$ Million)
Table 147. Roche Recent Development
Table 148. AstraZeneca Company Detail
Table 149. AstraZeneca Business Overview
Table 150. AstraZeneca Targeted Drugs for NSCLC Product
Table 151. AstraZeneca Revenue in Targeted Drugs for NSCLC Business (2019-2024) & (US$ Million)
Table 152. AstraZeneca Recent Development
Table 153. Cipla Company Detail
Table 154. Cipla Business Overview
Table 155. Cipla Targeted Drugs for NSCLC Product
Table 156. Cipla Revenue in Targeted Drugs for NSCLC Business (2019-2024) & (US$ Million)
Table 157. Cipla Recent Development
Table 158. Teva Company Detail
Table 159. Teva Business Overview
Table 160. Teva Targeted Drugs for NSCLC Product
Table 161. Teva Revenue in Targeted Drugs for NSCLC Business (2019-2024) & (US$ Million)
Table 162. Teva Recent Development
Table 163. OSI Pharmaceuticals Company Detail
Table 164. OSI Pharmaceuticals Business Overview
Table 165. OSI Pharmaceuticals Targeted Drugs for NSCLC Product
Table 166. OSI Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2019-2024) & (US$ Million)
Table 167. OSI Pharmaceuticals Recent Development
Table 168. Glenmark Pharmaceuticals Company Detail
Table 169. Glenmark Pharmaceuticals Business Overview
Table 170. Glenmark Pharmaceuticals Targeted Drugs for NSCLC Product
Table 171. Glenmark Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2019-2024) & (US$ Million)
Table 172. Glenmark Pharmaceuticals Recent Development
Table 173. Natco Pharma Company Detail
Table 174. Natco Pharma Business Overview
Table 175. Natco Pharma Targeted Drugs for NSCLC Product
Table 176. Natco Pharma Revenue in Targeted Drugs for NSCLC Business (2019-2024) & (US$ Million)
Table 177. Natco Pharma Recent Development
Table 178. Research Programs/Design for This Report
Table 179. Key Data Information from Secondary Sources
Table 180. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Targeted Drugs for NSCLC Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Targeted Drugs for NSCLC Market Share by Type: 2023 VS 2030
Figure 3. Target EGFR Features
Figure 4. Target ALK Features
Figure 5. Target HER2 Features
Figure 6. Target ROS1 Features
Figure 7. Target BRAF Features
Figure 8. Target MEK Features
Figure 9. Target VEGFR2 Features
Figure 10. Target VEGF Features
Figure 11. Target MET Features
Figure 12. Global Targeted Drugs for NSCLC Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 13. Global Targeted Drugs for NSCLC Market Share by Application: 2023 VS 2030
Figure 14. Squamous Cell Carcinoma of NSCLC Case Studies
Figure 15. Adenocarcinoma of NSCLC Case Studies
Figure 16. Large Cell Carcinoma of NSCLC Case Studies
Figure 17. Targeted Drugs for NSCLC Report Years Considered
Figure 18. Global Targeted Drugs for NSCLC Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 19. Global Targeted Drugs for NSCLC Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 20. Global Targeted Drugs for NSCLC Market Share by Region: 2023 VS 2030
Figure 21. Global Targeted Drugs for NSCLC Market Share by Players in 2023
Figure 22. Global Top Targeted Drugs for NSCLC Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for NSCLC as of 2023)
Figure 23. The Top 10 and 5 Players Market Share by Targeted Drugs for NSCLC Revenue in 2023
Figure 24. North America Targeted Drugs for NSCLC Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. North America Targeted Drugs for NSCLC Market Share by Country (2019-2030)
Figure 26. United States Targeted Drugs for NSCLC Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Canada Targeted Drugs for NSCLC Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Europe Targeted Drugs for NSCLC Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Europe Targeted Drugs for NSCLC Market Share by Country (2019-2030)
Figure 30. Germany Targeted Drugs for NSCLC Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. France Targeted Drugs for NSCLC Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. U.K. Targeted Drugs for NSCLC Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Italy Targeted Drugs for NSCLC Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Russia Targeted Drugs for NSCLC Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Nordic Countries Targeted Drugs for NSCLC Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Asia-Pacific Targeted Drugs for NSCLC Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Asia-Pacific Targeted Drugs for NSCLC Market Share by Region (2019-2030)
Figure 38. China Targeted Drugs for NSCLC Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Japan Targeted Drugs for NSCLC Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. South Korea Targeted Drugs for NSCLC Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Southeast Asia Targeted Drugs for NSCLC Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. India Targeted Drugs for NSCLC Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Australia Targeted Drugs for NSCLC Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Latin America Targeted Drugs for NSCLC Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Latin America Targeted Drugs for NSCLC Market Share by Country (2019-2030)
Figure 46. Mexico Targeted Drugs for NSCLC Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Brazil Targeted Drugs for NSCLC Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Middle East & Africa Targeted Drugs for NSCLC Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Middle East & Africa Targeted Drugs for NSCLC Market Share by Country (2019-2030)
Figure 50. Turkey Targeted Drugs for NSCLC Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 51. Saudi Arabia Targeted Drugs for NSCLC Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 52. Allergan Revenue Growth Rate in Targeted Drugs for NSCLC Business (2019-2024)
Figure 53. Amgen Revenue Growth Rate in Targeted Drugs for NSCLC Business (2019-2024)
Figure 54. ARIAD Pharmaceuticals (Takeda) Revenue Growth Rate in Targeted Drugs for NSCLC Business (2019-2024)
Figure 55. Beacon Pharma Limited Revenue Growth Rate in Targeted Drugs for NSCLC Business (2019-2024)
Figure 56. BeiGene Revenue Growth Rate in Targeted Drugs for NSCLC Business (2019-2024)
Figure 57. Biocon Revenue Growth Rate in Targeted Drugs for NSCLC Business (2019-2024)
Figure 58. Boehringer-Ingelheim Revenue Growth Rate in Targeted Drugs for NSCLC Business (2019-2024)
Figure 59. Celgene Corporation Revenue Growth Rate in Targeted Drugs for NSCLC Business (2019-2024)
Figure 60. Drug International Limted Revenue Growth Rate in Targeted Drugs for NSCLC Business (2019-2024)
Figure 61. Fujifilm Kyowa Kirin Biologics Revenue Growth Rate in Targeted Drugs for NSCLC Business (2019-2024)
Figure 62. Genvio Pharma Limited Revenue Growth Rate in Targeted Drugs for NSCLC Business (2019-2024)
Figure 63. Hetero Drugs Revenue Growth Rate in Targeted Drugs for NSCLC Business (2019-2024)
Figure 64. ImClone Systems (Eli Lilly) Revenue Growth Rate in Targeted Drugs for NSCLC Business (2019-2024)
Figure 65. Incepta Pharmaceuticals Revenue Growth Rate in Targeted Drugs for NSCLC Business (2019-2024)
Figure 66. Mylan Revenue Growth Rate in Targeted Drugs for NSCLC Business (2019-2024)
Figure 67. Novartis Revenue Growth Rate in Targeted Drugs for NSCLC Business (2019-2024)
Figure 68. Pfizer Revenue Growth Rate in Targeted Drugs for NSCLC Business (2019-2024)
Figure 69. Reliance Lifesciences Revenue Growth Rate in Targeted Drugs for NSCLC Business (2019-2024)
Figure 70. Roche Revenue Growth Rate in Targeted Drugs for NSCLC Business (2019-2024)
Figure 71. AstraZeneca Revenue Growth Rate in Targeted Drugs for NSCLC Business (2019-2024)
Figure 72. Cipla Revenue Growth Rate in Targeted Drugs for NSCLC Business (2019-2024)
Figure 73. Teva Revenue Growth Rate in Targeted Drugs for NSCLC Business (2019-2024)
Figure 74. OSI Pharmaceuticals Revenue Growth Rate in Targeted Drugs for NSCLC Business (2019-2024)
Figure 75. Glenmark Pharmaceuticals Revenue Growth Rate in Targeted Drugs for NSCLC Business (2019-2024)
Figure 76. Natco Pharma Revenue Growth Rate in Targeted Drugs for NSCLC Business (2019-2024)
Figure 77. Bottom-up and Top-down Approaches for This Report
Figure 78. Data Triangulation
Figure 79. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
